213 related articles for article (PubMed ID: 1707657)
1. Differential expression of the interleukin 2 receptor beta (p75) chain on human peripheral blood natural killer subsets.
Nishikawa K; Saito S; Morii T; Kato Y; Narita N; Ichijo M; Ohashi Y; Takeshita T; Sugamura K
Int Immunol; 1990; 2(6):481-6. PubMed ID: 1707657
[TBL] [Abstract][Full Text] [Related]
2. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D
J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
[TBL] [Abstract][Full Text] [Related]
3. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
Baume DM; Robertson MJ; Levine H; Manley TJ; Schow PW; Ritz J
Eur J Immunol; 1992 Jan; 22(1):1-6. PubMed ID: 1370410
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.
Nishikawa K; Saito S; Morii T; Hamada K; Ako H; Narita N; Ichijo M; Kurahayashi M; Sugamura K
Int Immunol; 1991 Aug; 3(8):743-50. PubMed ID: 1716974
[TBL] [Abstract][Full Text] [Related]
5. Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders.
Hoshino S; Oshimi K; Teramura M; Mizoguchi H
Blood; 1991 Dec; 78(12):3232-40. PubMed ID: 1835892
[TBL] [Abstract][Full Text] [Related]
6. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
7. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition.
Moretta A; Bottino C; Pende D; Tripodi G; Tambussi G; Viale O; Orengo A; Barbaresi M; Merli A; Ciccone E
J Exp Med; 1990 Dec; 172(6):1589-98. PubMed ID: 2147946
[TBL] [Abstract][Full Text] [Related]
8. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
Ortaldo JR; Frey J; Takeshita T; Sugamura K
Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
[TBL] [Abstract][Full Text] [Related]
9. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
[TBL] [Abstract][Full Text] [Related]
10. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
Carson WE; Fehniger TA; Caligiuri MA
Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
[TBL] [Abstract][Full Text] [Related]
11. CD16- CD56+ natural killer cells after bone marrow transplantation.
Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.
Voss SD; Robb RJ; Weil-Hillman G; Hank JA; Sugamura K; Tsudo M; Sondel PM
J Exp Med; 1990 Oct; 172(4):1101-14. PubMed ID: 1698909
[TBL] [Abstract][Full Text] [Related]
13. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
Gaddy J; Broxmeyer HE
Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
[TBL] [Abstract][Full Text] [Related]
14. The effect of interleukin 2 and transforming growth factor-beta 2 (TGF-beta 2) on the proliferation and natural killer activity of decidual CD16- CD56bright natural killer cells.
Saito S; Morii T; Enomoto M; Sakakura S; Nishikawa K; Narita N; Ichijo M
Cell Immunol; 1993 Dec; 152(2):605-13. PubMed ID: 7504983
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.
Zupo S; Azzoni L; Massara R; D'Amato A; Perussia B; Ferrarini M
J Clin Immunol; 1993 May; 13(3):228-36. PubMed ID: 7686565
[TBL] [Abstract][Full Text] [Related]
16. Identification and cellular distribution of the rat interleukin-2 receptor beta chain: induction of the IL-2R alpha- beta+ phenotype by major histocompatibility complex class I recognition during T cell development in vivo and by T cell receptor stimulation of CD4+8+ immature thymocytes in vitro.
Park JH; Hanke T; Hünig T
Eur J Immunol; 1996 Oct; 26(10):2371-5. PubMed ID: 8898947
[TBL] [Abstract][Full Text] [Related]
17. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
Carson WE; Giri JG; Lindemann MJ; Linett ML; Ahdieh M; Paxton R; Anderson D; Eisenmann J; Grabstein K; Caligiuri MA
J Exp Med; 1994 Oct; 180(4):1395-403. PubMed ID: 7523571
[TBL] [Abstract][Full Text] [Related]
18. Activation of natural killer cells via the p75 interleukin 2 receptor.
Phillips JH; Takeshita T; Sugamura K; Lanier LL
J Exp Med; 1989 Jul; 170(1):291-6. PubMed ID: 2787381
[TBL] [Abstract][Full Text] [Related]
19. Enhancement by stem cell factor of interleukin-2 (IL-2)-induced DNA synthesis in human decidual CD16- CD56bright natural killer cells mediated by increased expression of the IL-2 receptor alpha chain.
Umekage H; Saito S; Morikawa H
J Reprod Immunol; 1998 Oct; 40(1):1-24. PubMed ID: 9862254
[TBL] [Abstract][Full Text] [Related]
20. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
